161 related articles for article (PubMed ID: 37737263)
21. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
[TBL] [Abstract][Full Text] [Related]
22. Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers.
Marking U; Havervall S; Norin NG; Bladh O; Christ W; Gordon M; Ng H; Blom K; Phillipson M; Mangsbo S; Alm JJ; Smed-Sörensen A; Nilsson P; Hober S; Åberg M; Klingström J; Thålin C
Nat Commun; 2023 Mar; 14(1):1577. PubMed ID: 36949041
[TBL] [Abstract][Full Text] [Related]
23. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S; Arashiro T; Adachi Y; Moriyama S; Kinoshita H; Kanno T; Saito S; Katano H; Iida S; Ainai A; Kotaki R; Yamada S; Kuroda Y; Yamamoto T; Ishijima K; Park ES; Inoue Y; Kaku Y; Tobiume M; Iwata-Yoshikawa N; Shiwa-Sudo N; Tokunaga K; Ozono S; Hemmi T; Ueno A; Kishida N; Watanabe S; Nojima K; Seki Y; Mizukami T; Hasegawa H; Ebihara H; Maeda K; Fukushi S; Takahashi Y; Suzuki T
Med; 2022 Apr; 3(4):249-261.e4. PubMed ID: 35261995
[TBL] [Abstract][Full Text] [Related]
24. Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines.
Li D; Calderone R; Nsouli TM; Reznikov E; Bellanti JA
Allergy Asthma Proc; 2022 Sep; 43(5):419-430. PubMed ID: 36065108
[No Abstract] [Full Text] [Related]
25. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
26. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.
Gallichotte EN; Nehring M; Stromberg S; Young MC; Snell A; Daniels J; Pabilonia KL; VandeWoude S; Ehrhart N; Ebel GD
mSphere; 2022 Aug; 7(4):e0016922. PubMed ID: 35862798
[TBL] [Abstract][Full Text] [Related]
27. AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection.
Aksyuk AA; Bansal H; Wilkins D; Stanley AM; Sproule S; Maaske J; Sanikommui S; Hartman WR; Sobieszczyk ME; Falsey AR; Kelly EJ
Cell Rep Med; 2023 Jan; 4(1):100882. PubMed ID: 36610390
[TBL] [Abstract][Full Text] [Related]
28. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
29. Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine.
Azzi L; Dalla Gasperina D; Veronesi G; Shallak M; Maurino V; Baj A; Gianfagna F; Cavallo P; Dentali F; Tettamanti L; Maggi F; Maffioli LS; Tagliabue A; Accolla RS; Forlani G
EBioMedicine; 2023 Feb; 88():104435. PubMed ID: 36628844
[TBL] [Abstract][Full Text] [Related]
30. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
[TBL] [Abstract][Full Text] [Related]
31. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
32. A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects.
Martinuzzi E; Benzaquen J; Guerin O; Leroy S; Simon T; Ilie M; Hofman V; Allegra M; Tanga V; Michel E; Boutros J; Maniel C; Sicard A; Glaichenhaus N; Czerkinsky C; Blancou P; Hofman P; Marquette CH
Clin Infect Dis; 2022 Dec; 75(12):2053-2059. PubMed ID: 35579991
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines.
Liu S; Tsun JGS; Fung GPG; Lui GCY; Chan KYY; Chan PKS; Chan RWY
Front Immunol; 2023; 14():1127401. PubMed ID: 36793736
[TBL] [Abstract][Full Text] [Related]
34. Unveiling a New Perspective on Distinguishing Omicron Breakthrough Cases and Postimmune COVID-19-Naive Individuals: Insights from Antibody Profiles.
Zhang S; Dong C; Zhen Q; Shi C; Tian H; Li C; Kong X; Dai Q; Huang H; Simayi A; Zhu F; Xu Y; Hu J; Xu K; Chen L; Bao C; Jin H; Zhu L
Microbiol Spectr; 2023 Aug; 11(4):e0180823. PubMed ID: 37432106
[TBL] [Abstract][Full Text] [Related]
35. Detection of anti-SARS-CoV-2 antibodies in tears: Ocular surface immunity to COVID-19.
Guemes-Villahoz N; Burgos-Blasco B; Echevarria-Torres PL; Vidal-Villegas B; Rodriguez de la Peña A; Diaz-Valle D; Fernández-Vigo JI; Sánchez-Ramón S; Garcia-Feijoo J
Arch Soc Esp Oftalmol (Engl Ed); 2023 Jul; 98(7):397-403. PubMed ID: 37247663
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G.
Anderson M; Stec M; Gosha A; Mohammad T; Boler M; Tojo Suarez R; Behun D; Landay A; Cloherty G; Moy J
J Infect Dis; 2022 Nov; 226(11):1934-1942. PubMed ID: 36263799
[TBL] [Abstract][Full Text] [Related]
37. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
[TBL] [Abstract][Full Text] [Related]
38. Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Wei J; Matthews PC; Stoesser N; Newton JN; Diamond I; Studley R; Taylor N; Bell JI; Farrar J; Kolenchery J; Marsden BD; Hoosdally S; Jones EY; Stuart DI; Crook DW; Peto TEA; Walker AS; Pouwels KB; Eyre DW;
Nat Commun; 2023 May; 14(1):2799. PubMed ID: 37193713
[TBL] [Abstract][Full Text] [Related]
39. Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein.
den Hartog G; Andeweg SP; Hoeve CE; Smits G; Voordouw B; Eggink D; Knol MJ; van Binnendijk RS
Sci Rep; 2023 Oct; 13(1):18394. PubMed ID: 37884642
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay.
Liu H; Varvel S; Chen G; McConnell J; Caffrey R; Galdzicka M; Shabahang S
Front Immunol; 2022; 13():1039163. PubMed ID: 36505453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]